Oligonucleotide microarray analysis of estrogen receptor α-positive postmenopausal breast carcinomas: Identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen

Journal of Molecular Endocrinology

Volumn 39, Issue 3-4, 2007, Pages 305-318

  Tozlu Kara, S ^a,b   Roux, V ^c   Andrieu, C ^a,b   Vendrell, J ^b,d,e   Vacher, S ^a,b   Lazar, V ^c   Spyratos, F ^a,b   Tubiana Hulin, M ^a   Cohen, P ^b,d,e   Dessen, P ^c   Lidereau, R ^a,b   Bieche I ^a,b  

^a CENTRE RENÉ HUGUENIN   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HORMONE REGULATED PROLIFERATION ASSOCIATED PROTEIN 20; MESSENGER RNA; PROTEIN; TAMOXIFEN; TIMELESS PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; FEMALE; GENE IDENTIFICATION; GENOMICS; HORMONE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOG RANK TEST; LYMPH NODE METASTASIS; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATIENT IDENTIFICATION; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CALMODULIN-BINDING PROTEINS; CARCINOMA; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMENOPAUSE; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 35748949304     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-07-0001     Document Type: Article

References (24)

1. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC & Pons M 2000 Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Research 60 4130-4138.
2. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R & Vidaud M 1999 Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clinical Chemistry 45 1148-1156.
3. Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R & Vidaud M 2001 Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Research 61 1652-1658.
4. Demirpence E, Duchesne MJ, Badia E, Gagne D &Pons M 1993 MVLN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity. Journal of Steroid Biochemistry and Molecular Biology 46 355-364.
5. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA & Trent JM 1996 Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics 14 457-460.
6. Diab SG, Elledge RM & Clark GM 2000 Tumor characteristics and clinical outcome of elderly women with breast cancer. Journal of the National Cancer Institute 92 550-556.
7. Hanley J & McNeil B 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 29-36.
8. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC et al. 2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. American Journal of Clinical Oncology 23 732-740.
9. Kaplan EL & Meier P 1958 Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53 457-481.
10. Karp CM, Pan H, Zhang M, Bucldey DJ, Schuler LA & Buckley AR 2004 Identification of HRPAP20: a novel phosphoprotein that enhances growth and survival in hormone-responsive tumor cells. Cancer Research 64 1016-1025.
11. Karp CM, Shukla MN, Buckley DJ & Buckley AR 2007 HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion. Oncogene 26 1780-1788.
12. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R & Tuggle JT 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 607-616.
13. Mann H & Whitney D 1947 On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics 18 50-60.
14. McGuire WL 1980 Steroid hormone receptors in breast cancer treatment strategy. Recent Progress in Hormone Research 36 135-156.
15. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD et al. 2007 A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26 1507-1516.
16. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826.
17. Peto R, Pike MC & Armitage P 1977 Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer 35 1-39.
18. Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M & Pierotti MA 2005 Limits of predictive models using microarray data for breast cancer clinical treatment outcome. Journal of the National Cancer Institute 97 927-930.
19. Unsal-Kacmaz K, Mullen TE, Kaufmann WK & Sancar A 2005 Coupling of human circadian and cell cycles by the timeless protein. Molecular and Cellular Biology 25 3109-3116.
20. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mat M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536.
21. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R & Cohen PA 2005 Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocrine-Related Cancer 12 75-92.
22. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al. 2002 A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347 1999-2009.
23. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671-679.
24. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH & Brody LC 2002 BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nature Genetics 30 285-289.